Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
Tim
R W
RW
Duke University Medical Center, Durham, North Carolina 27710, USA.
Massey
J M
JM
Sanders
D B
DB
D015761:4-Aminopyridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000077770:Amifampridine; D001323:Autoantibodies / Q000097:blood; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy; D002648:Child; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004568:Electrodiagnosis; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015624:Lambert-Eaton Myasthenic Syndrome / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D011950:Receptors, Cholinergic / Q000276:immunology
D001323:Autoantibodies; D002800:Cholinesterase Inhibitors; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; D015761:4-Aminopyridine; D011729:Pyridostigmine Bromide; D000077770:Amifampridine